Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Revenue (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Revenue for 4 consecutive years, with $86.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 17.74% to $86.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $263.5 million, a 60.6% increase, with the full-year FY2025 number at $263.5 million, up 60.6% from a year prior.
  • Revenue was $86.8 million for Q4 2025 at Iovance Biotherapeutics, up from $67.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $86.8 million in Q4 2025 to a low of $238000.0 in Q2 2023.
  • A 3-year average of $39.0 million and a median of $49.3 million in 2025 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 15189.21% in 2024, then rose 15.2% in 2025.
  • Iovance Biotherapeutics' Revenue stood at $482000.0 in 2023, then surged by 15189.21% to $73.7 million in 2024, then grew by 17.74% to $86.8 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Revenue are $86.8 million (Q4 2025), $67.5 million (Q3 2025), and $60.0 million (Q2 2025).